We also evaluated the prognosis of lung cancer patients treated with EGFR tyrosine kinase inhibitors (TKI) and monoclonal antibodies (MAB) and whether in this subgroup, co-occurrence of CNVs and mutations affected prognosis compared to those having EGFR mutation alone. Here, EGFR is linked to lung cancer.